Get the Stockscreener App
0.6949
0.27%
-0.0019
After Hours:
.72
0.0251
+3.61%
VolitionRX Ltd stock is traded at $0.6949, with a volume of 160.45K.
It is down -0.27% in the last 24 hours and up +16.75% over the past month.
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
See More
Previous Close:
$0.6968
Open:
$0.7
24h Volume:
160.45K
Relative Volume:
1.29
Market Cap:
$64.39M
Revenue:
$775.30K
Net Income/Loss:
$-35.32M
P/E Ratio:
-1.2409
EPS:
-0.56
Net Cash Flow:
$-19.15M
1W Performance:
-12.47%
1M Performance:
+16.75%
6M Performance:
-7.72%
1Y Performance:
-9.75%
1-Day Range:
$0.62
$0.7201
1-Week Range:
$0.62
$0.80
52-Week Range:
$0.4301
$1.23
VolitionRX Ltd Stock (VNRX) Company Profile
Name
VolitionRX Ltd
Sector
Industry
Phone
646 650 1351
Address
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.6949 | 64.39M | 775.30K | -35.32M | -19.15M | -0.51 |
|
TMO
Thermo Fisher Scientific Inc
|
529.63 | 202.58B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
239.69 | 173.12B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
137.97 | 39.35B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
200.84 | 36.45B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
421.75 | 34.53B | 3.84B | 866.24M | 792.60M | 10.37 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-01-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-17-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-10-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-18 | Initiated | Maxim Group | Buy |
| May-14-18 | Reiterated | The Benchmark Company | Buy |
| Sep-07-16 | Reiterated | Rodman & Renshaw | Buy |
| Feb-01-16 | Initiated | Rodman & Renshaw | Buy |
View All
VolitionRX Ltd Stock (VNRX) Latest News
VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World
VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey
VolitionRX: Q3 Earnings Snapshot - New Haven Register
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
VolitionRx Posts Strong Q3 Growth and Strategic Advances - TipRanks
Lagoda Investment Management's Strategic Acquisition in Volition - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in VolitionRX Ltd - GuruFocus.com
VolitionRX Ltd Reports Q3 Revenue of $475,000, Missing Estimates of $0.65 Million - GuruFocus.com
VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to L - GuruFocus.com
StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - MarketBeat
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update - Yahoo Finance
Volition Appoints Timothy I. Still as Chairman – Company Announcement - Financial Times
VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - Defense World
Abionic’s test enters increasingly competitive sepsis fray - BioWorld Online
VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com - Defense World
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar - Quantisnow
VolitionRx adds Dr. Ethel Rubin to its board By Investing.com - Investing.com South Africa
VolitionRx adds Dr. Ethel Rubin to its board - Investing.com India
Volition Appoints Dr. Ethel Rubin as an Independent Director - Quantisnow
Volition Appoints Dr. Ethel Rubin as an Independent Director – Company Announcement - Financial Times
VolitionRx announces executive employment updates - Investing.com India
Agency News | ⚡Tamil Nadu’s Veterinary Varsity Directed by High Court To Consider Transgender Student’s Application - LatestLY
Madras HC directs TN veterinary varsity to not reject transgender's application over identity - Hindustan Times
Madras High Court Orders TN Veterinary University to Accept Transgender Candidate's Application - Law Trend
Don't reject transgender's application over identity HC tells TN veterinary varsity - The Week
Madras High Court Upholds Transgender Rights for Veterinary Course Admissions - Devdiscourse
Volato Facing Class-action WARN Act Lawsuit - Aviation International News
VolitionRx offers oncology assets for licensing - Investing.com India
VolitionRx offers oncology assets for licensing By Investing.com - Investing.com Australia
Volition Announces Board of Directors - TechBuzz News
CRYPTOPSY's New Shirts Are Very Serious - Metal Injection
Terminated Volato Employees File Class Action Lawsuit - FLYING
LifeLabs workers in GTA poised to strike if deal not reached by Saturday - CP24
Investing in VolitionRX Ltd (VNRX): What You Must Know - Knox Daily
Volition Hosts KOL Roundtable on Sepsis - Yahoo Finance
VolitionRX Ltd [VNRX] Records 200-Day SMA of $0.7821 - Knox Daily
The Potential Rise in the Price of VolitionRX Ltd (VNRX) following insiders activity - Knox Daily
VNRX: Nu.Q Vet Test is now available in 17 countries. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR (human cancer detection method) and Nu.Q NET for sepsis. $7.0 million fi - Yahoo Finance
Understanding the Risks of Investing in VolitionRX Ltd (VNRX) - Knox Daily
Comparing OncoCyte (NASDAQ:OCX) & VolitionRx (NYSE:VNRX) - Defense World
VolitionRx (NYSEAMERICAN:VNRX) Stock Price Passes Above 50-Day Moving Average of $0.00 - Defense World
VolitionRx Limited (NYSE:VNRX) Director Guy Archibald Innes Purchases 150,000 Shares - Defense World
VolitionRX Ltd (VNRX) Q2 2024 Earnings Call Transcript Highlight - GuruFocus.com
Benchmark Reiterates Hold Rating for VolitionRx (NYSE:VNRX) - Defense World
VolitionRx Limited (AMEX:VNRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: VolitionRx reports strong growth and optimistic outlook - Investing.com
VolitionRX: Q2 Earnings Snapshot - San Antonio Express-News
VolitionRX Ltd Stock (VNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):